Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:41:19.527Z.
Calculation as of: 2026-10-06T15:41:19.527Z.
Quote observation: 2026-10-06T15:40:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9f8c720c17565e189db9218018d8859aabec9e8167d5f057fd0cc602bb9808d0
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerus Corporation (CERS) | $474.59M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.83M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $479.89M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $468.45M | N/A | 0.08 | 0.16 | 0.16 |
| Arvinas, Inc. (ARVN)vs › | $482.94M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $460.30M | N/A | 6.07 | 3.14 | 2.42 |
| Puma Biotechnology, Inc. (PBYI)vs › | $490.16M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $491.69M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $453.54M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $454.10M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute